Khaled Adil, MD
Radiation Oncology · Albany, NYNPI 1669944237
Payments from drug & device makers
What this record shows
Viewray Technologies Inc accounts for 78.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $2,086 and has fallen 95.4% since, to $95 in 2024.
Across 21 payments — averaging $127.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viewray Technologies Inc$2K
- AstraZeneca$244
- Icotec Medical Inc.$156
- Elekta Instrument AB$95
- Elekta, Inc.$32
- Sirtex Medical Inc$27
- plus $34 from 2 others
What the payments were for
- Travel & lodging$1,54558%
- Food & beverage$1,12942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viewray Technologies Inc | 10 | $2,086 |
| AstraZeneca | 3 | $244 |
| Icotec Medical Inc. | 1 | $156 |
| Elekta Instrument AB | 1 | $95 |
| Elekta, Inc. | 3 | $32 |
| Sirtex Medical Inc | 1 | $27 |
| Fortovia Therapeutics, Inc. | 1 | $17 |
| Mevion_medical_systems_inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,674 in reported general payments places this provider in the 80th percentile of 397 radiation oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lidocaine Hcl ViscousLidocaine Hcl | 41 | $671 |
| Dexamethasone | 18 | $181 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $97 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Albany
- Chung ChungSyracuse$3.1M
- Michael ZelefskyNew York$946K
- Jeffrey BogartSyracuse$772K
- Steven FinkelsteinSyracuse$578K
- Shawn ZimbergPlainview$411K
- Edward ObedianOyster Bay$391K
- Nancy LeeNew York$233K
- Dheerendra PrasadBuffalo$178K
- Robert SamsteinNew York$125K
- Jalal AhmedNew York$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.